{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:39Z","timestamp":1786982379569,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s12325-021-01970-w","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T07:03:02Z","timestamp":1636441382000},"page":"2468-2486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-\u03b1 Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study"],"prefix":"10.1007","volume":"39","author":[{"given":"Johan","family":"Dal\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushri","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Svedbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Puenpatom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-3980","authenticated-orcid":false,"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"1970_CR1","unstructured":"Handout on Health: Rheumatoid Arthritis. National Institute of Arthritis and Musculoskeletal and Skin Diseases; 2014."},{"issue":"7","key":"1970_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2217\/ijr.12.61","volume":"6","author":"S Lipton","year":"2012","unstructured":"Lipton S, Deodhar A. The new ASAS classification criteria for axial and peripheral spondyloarthritis. Int J Clin Rheumatol. 2012;6(7):675\u201382.","journal-title":"Int J Clin Rheumatol"},{"issue":"6","key":"1970_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1970_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","volume":"71","author":"L Gossec","year":"2012","unstructured":"Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1970_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0889-857X(21)00171-X","volume":"19","author":"T Pincus","year":"1993","unstructured":"Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am. 1993;19(1):123\u201351.","journal-title":"Rheum Dis Clin North Am"},{"key":"1970_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/3-7643-7438-1_2","volume-title":"History of development of TNF inhibitors. TNF-alpha inhibitors","author":"SR Stevens","year":"2006","unstructured":"Stevens SR, Chang TH. History of development of TNF inhibitors. TNF-alpha inhibitors. Springer; 2006. p. 9\u201322."},{"issue":"8","key":"1970_CR7","first-page":"1631","volume":"29","author":"D Aletaha","year":"2002","unstructured":"Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol. 2002;29(8):1631\u20138.","journal-title":"J Rheumatol"},{"key":"1970_CR8","first-page":"102","volume":"44","author":"J Fries","year":"1996","unstructured":"Fries J. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl. 1996;44:102\u20136.","journal-title":"J Rheumatol Suppl"},{"issue":"12","key":"1970_CR9","first-page":"1885","volume":"19","author":"T Pincus","year":"1992","unstructured":"Pincus T, Marcum S, Callahan L. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992;19(12):1885\u201394.","journal-title":"J Rheumatol"},{"issue":"7","key":"1970_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00296-016-3423-5","volume":"36","author":"J Dalen","year":"2016","unstructured":"Dalen J, Svedbom A, Black CM, Lyu R, Ding Q, Sajjan S, et al. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. Rheumatol Int. 2016;36(7):987\u201395.","journal-title":"Rheumatol Int"},{"issue":"7","key":"1970_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0149-2918(08)80063-X","volume":"30","author":"B Tang","year":"2008","unstructured":"Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375\u201384.","journal-title":"Clin Ther"},{"key":"1970_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/bcp.14387","volume":"87","author":"M Belhassen","year":"2020","unstructured":"Belhassen M, Tubach F, Hudry C, Woronoff-Lemsi M, Levy-Bachelot L, Van Ganse E, et al. Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases. Brit J Clin Pharmacol. 2020;87:163\u201377.","journal-title":"Brit J Clin Pharmacol."},{"issue":"7","key":"1970_CR13","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/rheumatology\/key099","volume":"57","author":"K Ziegelbauer","year":"2018","unstructured":"Ziegelbauer K, Kostev K, Hubinger M, Dombrowski S, Friedrichs M, Friedel H, et al. The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany. Rheumatology (UK). 2018;57(7):1276\u201381.","journal-title":"Rheumatology (UK)"},{"key":"1970_CR14","unstructured":"Forsblad-d'Elia H, Jacobsson LT, Feltelius N, Husmark T, Szentpetery A, Wallman JK, et al. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid axial spondylartrit och psoriasisartrit 2019. Svensk Reumatologisk F\u00f6rening; 2019."},{"key":"1970_CR15","unstructured":"Gjertsson I, Lampa J, Sv\u00e4rd A, S\u00f6dergren A, Turesson C. Riktlinjer f\u00f6r l\u00e4kemedelsbehandling vid reumatoid artrit. Svensk Reumatologisk F\u00f6rening; 2019."},{"key":"1970_CR16","unstructured":"Welfare NBoHa. Quality declaration, statistics on pharmaceuticals for 2018. 2019."},{"issue":"1","key":"1970_CR17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44\u20137.","journal-title":"Value Health"},{"key":"1970_CR18","unstructured":"Statistics Sweden. Genomsnittlig m\u00e5nadsl\u00f6n, l\u00f6n i fasta priser och l\u00f6nespridning efter utbildningsniv\u00e5 SUN 2000 och k\u00f6n. \u00c5r 1991\u20132019, [updated 13 Jan 2021. Available from: https:\/\/www.scb.se\/hitta-statistik\/sverige-i-siffror\/utbildning-jobb-och-pengar\/medelloner-i-sverige\/."},{"issue":"1","key":"1970_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","volume":"70","author":"PR Rosenbaum","year":"1983","unstructured":"Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41\u201355.","journal-title":"Biometrika"},{"issue":"25","key":"1970_CR20","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"3","key":"1970_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/pan\/mpl013","volume":"15","author":"DE Ho","year":"2007","unstructured":"Ho DE, Imai K, King G, Stuart EA. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Polit Anal. 2007;15(3):199\u2013236.","journal-title":"Polit Anal"},{"key":"1970_CR22","first-page":"196","volume-title":"Misunderstandings between experimentalists and observationalists about causal inference. Field experiments and their critics","author":"K Imai","year":"2014","unstructured":"Imai K, King G, Stuart EA. Misunderstandings between experimentalists and observationalists about causal inference. Field experiments and their critics. Yale: Yale University Press; 2014. p. 196\u2013227."},{"issue":"5","key":"1970_CR23","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00019053-199813050-00002","volume":"13","author":"A Desgagn\u00e9","year":"1998","unstructured":"Desgagn\u00e9 A, Castilloux A-M, Angers J-F, Le Lorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13(5):487\u201397.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"1970_CR24","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Website and R package for computing E-values. Epidemiology. 2018;29(5):e45.","journal-title":"Epidemiology"},{"issue":"4","key":"1970_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1970_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2340\/00015555-2329","volume":"96","author":"A Svedbom","year":"2016","unstructured":"Svedbom A, Dal\u00e9n J, Mamolo C, Cappelleri JC, Mallbris L, Petersson IF, et al. Economic burden of psoriasis and potential cost offsets with biologic treatment: a Swedish Register Analysis. Acta Derm Venereol. 2016;96(5):651\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"1970_CR27","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1080\/13696998.2019.1652183","volume":"22","author":"M Tarallo","year":"2019","unstructured":"Tarallo M, Onishchenko K, Alexopoulos ST. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK. J Med Econ. 2019;22(11):1162\u201370.","journal-title":"J Med Econ"},{"issue":"3","key":"1970_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40801-018-0139-8","volume":"5","author":"R Sruamsiri","year":"2018","unstructured":"Sruamsiri R, Kameda H, Mahlich J. Persistence with biological disease-modifying antirheumatic drugs and its associated resource utilization and costs. Drugs-real World Outcomes. 2018;5(3):169\u201379.","journal-title":"Drugs-real World Outcomes"},{"key":"1970_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/CEOR.S108730","volume":"9","author":"L Degli Esposti","year":"2017","unstructured":"Degli Esposti L, Favalli EG, Sangiorgi D, Di Turi R, Farina G, Gambera M, et al. Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. ClinicoEcon Outcomes Res CEOR. 2017;9:9.","journal-title":"ClinicoEcon Outcomes Res CEOR"},{"issue":"8","key":"1970_CR30","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s12325-016-0371-0","volume":"33","author":"GW Cannon","year":"2016","unstructured":"Cannon GW, DuVall SL, Haroldsen CL, Caplan L, Curtis JR, Michaud K, et al. Clinical outcomes and biologic costs of switching between tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. Adv Ther. 2016;33(8):1347\u201359.","journal-title":"Adv Ther"},{"issue":"4","key":"1970_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3111\/13696998.2014.893241","volume":"17","author":"B Meissner","year":"2014","unstructured":"Meissner B, Trivedi D, You M, Rosenblatt L. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ. 2014;17(4):259\u201365.","journal-title":"J Med Econ"},{"issue":"6","key":"1970_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3111\/13696998.2016.1142448","volume":"19","author":"N Rashid","year":"2016","unstructured":"Rashid N, Lin AT, Aranda G Jr, Lin KJ, Guerrero VN, Nadkarni A, et al. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system. J Med Econ. 2016;19(6):568\u201375.","journal-title":"J Med Econ"},{"key":"1970_CR33","doi-asserted-by":"crossref","unstructured":"Hur P, Kim N, Dai D, Piao OW, Zheng JZ, Yi E. Healthcare cost and utilization associated with biologic treatment patterns among patients with psoriatic arthritis: analyses from a large US Claims database. Drugs-Real World Outcomes. 2020, pp 1\u201310.","DOI":"10.1007\/s40801-020-00217-4"},{"issue":"4","key":"1970_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/13696998.2019.1571498","volume":"22","author":"A Shahabi","year":"2019","unstructured":"Shahabi A, Shafrin J, Zhao L, Green S, Curtice T, Marshall A, et al. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients. J Med Econ. 2019;22(4):350\u20138.","journal-title":"J Med Econ"},{"issue":"6","key":"1970_CR35","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.clinthera.2019.04.032","volume":"41","author":"J Vanderpoel","year":"2019","unstructured":"Vanderpoel J, Tkacz J, Brady BL, Ellis L. Health care resource utilization and costs associated with switching biologics in rheumatoid arthritis. Clin Ther. 2019;41(6):1080-9.e5.","journal-title":"Clin Ther"},{"key":"1970_CR36","first-page":"SP338","volume":"24","author":"T Gu","year":"2018","unstructured":"Gu T, Mutebi A, Stolshek BS, Tan H. Cost of biologic treatment persistence or switching in rheumatoid arthritis. Am J Managed Care. 2018;24:SP338\u2013435.","journal-title":"Am J Managed Care."},{"issue":"1","key":"1970_CR37","first-page":"27","volume":"27","author":"E Yi","year":"2021","unstructured":"Yi E, Dai D, Piao OW, Zheng JZ, Park Y. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis. J Manag Care Spec Pharm. 2021;27(1):27\u201336.","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"1970_CR38","doi-asserted-by":"publisher","first-page":"A35","DOI":"10.1016\/j.jval.2012.03.198","volume":"15","author":"H Wang","year":"2012","unstructured":"Wang H, Wang Y, Michael T, Hopkins B, Bodoria M, Sondhi M, et al. PMS9 biologic therapy patterns and associated costs in rheumatoid arthritis patients who initiated a tumor necrosis factor antagonist over two years. Value Health. 2012;15(4):A35.","journal-title":"Value Health"},{"key":"1970_CR39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.","journal-title":"BMC Public Health"},{"issue":"7","key":"1970_CR40","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726\u201335.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1970_CR41","unstructured":"Dalen J, Luttropp K, Olofsson T, Black C, Puenpatom A, editors. Cost of non-persistence in the treatment with subcutaneous tumor necrosis factor-alpha inhibitors of inflammatory arthritis: a propensity score matching approach. Arthritis & Rheumatology; 2020: Wiley 111 River St, Hoboken 07030\u20135774, NJ USA."},{"issue":"3","key":"1970_CR42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/03009740601089580","volume":"36","author":"L Jacobsson","year":"2007","unstructured":"Jacobsson L, Lindroth Y, Marsal L, Juran E, Bergstr\u00f6m U, Kobelt G. Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malm\u00f6 Sweden. Scand J Rheumatol. 2007;36(3):179\u201383.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"1970_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2474-15-176","volume":"15","author":"J Hubertsson","year":"2014","unstructured":"Hubertsson J, Englund M, Hallg\u00e5rde U, Lidwall U, L\u00f6fvendahl S, Petersson IF. Sick leave patterns in common musculoskeletal disorders\u2014a study of doctor prescribed sick leave. BMC Musculoskelet Disord. 2014;15(1):1\u20139.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"1970_CR44","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/ard.2005.045807","volume":"65","author":"K Puolakka","year":"2006","unstructured":"Puolakka K, Kautiainen H, Pekurinen M, M\u00f6tt\u00f6nen T, Hannonen P, Korpela M, et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients\u2019 sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis. 2006;65(7):899\u2013904.","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s12325-022-02043-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01970-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01970-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T06:34:25Z","timestamp":1653028465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01970-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1970"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01970-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-022-02043-2","URL":"https:\/\/doi.org\/10.1007\/s12325-022-02043-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}